



THOMSON MEDICAL GROUP LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

**THOMSON MEDICAL GROUP LIMITED ISSUES S\$175,000,000 4.05% NOTES DUE 2025
PURSUANT TO THE S\$500,000,000 MULTICURRENCY DEBT ISSUANCE PROGRAMME OF
THOMSON MEDICAL GROUP LIMITED**

Further to the announcement by Thomson Medical Group Limited (the "**Company**") on 20 January 2020, the board of directors (the "**Board**") of the Company wishes to announce that it has issued S\$175,000,000 in aggregate principal amount of 4.05% notes due 2025 (the "**Series 002 Notes**"). The Series 002 Notes were issued pursuant to the S\$500,000,000 Multicurrency Debt Issuance Programme established by the Company on 28 June 2019 (the "**Programme**"). DBS Bank Ltd., Maybank Kim Eng Securities Pte. Ltd. and Standard Chartered Bank (Singapore) Limited have been appointed as the joint lead managers and joint bookrunners in relation to the Series 002 Notes.

Approval in-principle has been received from the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") for the listing and quotation of the Series 002 Notes on the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made, opinions expressed or reports contained herein. Approval in-principle from, admission to the Official List of, and the listing and quotation of the Series 002 Notes on, the SGX-ST are not to be taken as an indication of the merits of the Company, its subsidiaries, its associated companies (if any), the Programme or the Series 002 Notes. The Series 002 Notes are expected to be listed on the SGX-ST on 29 January 2020.

By Order of the Board
THOMSON MEDICAL GROUP LIMITED

Wilson Sam
Executive Director and Group Chief Financial Officer
28 January 2020